Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
Table 1
Patients characteristics according to mutational status. Compared to CALR-mutated patients, patients with JAK2 mutation were older () and had higher hemoglobin levels ().
Characteristics
JAK2-mutated patients (number = 16)
CALR-mutated patients (number = 10)
MPL-mutated patients (number = 3)
“Triple-negative” patients (number = 1)
Median age, years (range)
73 (67–84)
65.5 (44–82)
76 (72–76)
67
Male sex, number (%)
9 (56)
6 (60)
1 (33.3)
0 (0)
Median allele burden, % (range)
89 (0.4–99)
56.5 (52–98)
NA
NA
Median WBC, ×109/L (range)
10.6 (2.5–157.6)
7.15 (2.3–48.3)
6.2 (4.9–25)
6.7
Median hemoglobin, g/dL (range)
11.1 (8.6–15.1)
9.3 (7.7–14)
9.7 (7.2–9.9)
8.5
Median platelet count, ×109/L (range)
280 (41–507)
195.5 (86–419)
196 (46–303)
632
High/intermediate 2 IPSS category, number (%)
9 (56)
6 (60)
3 (100)
1 (100)
Unfavorable karyotype, number (%)
8 (50)
2 (20)
2 (66.6)
1 (100)
Diagnosis, number (%)
PMF
8 (50)
6 (60)
3 (100)
1 (100)
PET
3 (19)
2 (20)
—
—
PPV
5 (31)
2 (20)
—
—
BM fibrosis grade ≥ 2, number (%)
12 (75)
10 (100)
2 (66.6)
0 (0)
Patients with splenomegaly, number (%)
14 (87.5)
8 (80)
3 (100)
0 (0)
WBC: white blood cells; IPSS: International Prognostic Scoring System; PMF: primary myelofibrosis; NA: not available. Splenomegaly was evaluated by palpation as cm below costal margin. Only patients with a spleen palpable ≥ 5 cm below costal margin by palpation were considered as carrying splenomegaly.
